drugset

drugset / Trial / NCT04287920

Acamprosate Safe to Use in Individuals With Liver Disease.

NCT04287920 ↗

Phase 2 Completed 12 enrolled Mayo Clinic

Non-randomizedSequentialOpen-labelTreatment

Summary

Is acamprosate safe to use in individuals with liver disease.

Timeline

Start: 2020-09-21
Primary completion: 2022-01-05
Completion: 2022-01-05

Publications

Wu T, Mousa OY, Kulai T, Larson C, Olofson A, Kamath PS, Shah VH, Taner T, Sanchez W, Simonetto DA. Safety of Acamprosate in Patients With Alcohol-Associated Liver Disease: A Single-Arm Phase 2 Trial. Mayo Clin Proc. 2025 Jun;100(6):954-961. doi: 10.1016/j.mayocp.2024.12.013. Epub 2025 Mar 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acamprosate	Small molecule	666 mg	Oral

Indications